Advertisement

Topics

Canada approves AbbVie's Maviret as treatment for hepatitis C

04:42 EDT 21 Aug 2017 | SmartBrief

Maviret, AbbVie's glecaprevir/pibrentasvir drug developed as a treatment for adults with chronic hepatitis C virus across gen -More

Original Article: Canada approves AbbVie's Maviret as treatment for hepatitis C

NEXT ARTICLE

More From BioPortfolio on "Canada approves AbbVie's Maviret as treatment for hepatitis C"

Advertisement
Quick Search
Advertisement
Advertisement

 

Relevant Topics

The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...

Drug Discovery
Clinical Approvals Clinical Trials Drug Approvals Drug Delivery Drug Discovery Generics Drugs Prescription Drugs In the fields of medicine, biotechnology and pharmacology, drug discovery is the process by which drugs are dis...

Gastroenterology
Astroesophageal Reflux Disease (GERD) Barrett's Esophagus Celiac Disease Cholesterol Crohn's Disease Gastroenterology Hepatitis Hepatology Irritable Bowel Syndrome (IBS) Pancreatitis Peptic Ulcer Disease...